Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16520138 | 0.90 | KMT2A (0.50) | MEN1KMT2AGPR119MMP13STS | |
| SCHEMBL4973467 | 0.89 | MEN1 (0.48) | MEN1KMT2AGPR119MMP13STS | |
| SCHEMBL3319115 | 0.86 | MEN1 (0.45) | MEN1KMT2AGPR119MMP13P2RX7 | |
| SCHEMBL19205366 | 0.85 | MEN1 (0.46) | MEN1KMT2AGPR119MMP13P2RX7 | |
| SCHEMBL23531641 | 0.83 | KMT2A (0.50) | MEN1KMT2AGPR119MMP13STS | |
| SCHEMBL619491 | 0.82 | KMT2A (0.49) | MEN1KMT2AGPR119MMP13STS | |
| SCHEMBL30451018 | 0.81 | GPR119 (0.68) | MEN1KMT2AGPR119MMP13 | |
| SCHEMBL25547276 | 0.81 | GPR119 (0.68) | MEN1KMT2AGPR119MMP13 | |
| SCHEMBL31420242 | 0.81 | KMT2A (0.53) | MEN1KMT2AGPR119MMP13STS | |
| SCHEMBL25284834 | 0.80 | KMT2A (0.47) | MEN1KMT2AGPR119MMP13STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| EP-1761491-A1 | NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006001752-A1 | NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | CCR5, CXCR1, CCR2 | MEN1 4736/4885KMT2A 3512/4885GPR119 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.